Potvin C or B? [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2012-06-02 20:54 (4317 d 17:58 ago) – Posting: # 8656
Views: 11,156

Gossip:

One regulator (I leave it to your imagination which one of EMA’s working parties he belongs to) told me that

Our [i.e., his agency’s] statisticians don’t believe* that in Potvin’s Method C the patient’s risk is preserved at ~5%. They suggest to use only Method B because application of Pocock’s α 0.0294 is well known.

I suggested to tell them to have a closer look at the empiric alphas (the endless tables in the paper). BTW, specifically Method C (not B!) is recommended by the FDA and in the recent Canadian GL.



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
122 visitors (0 registered, 122 guests [including 0 identified bots]).
Forum time: 13:53 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5